NEW YORK, Dec. 21 /PRNewswire-FirstCall/ -- TMI Alzheimer’s Centers, Inc. (OTC Bulletin Board: “TMIA”) In the 1st Joint Conference of the EEG & Clinical Neuroscience Society (ECNS) & the International Society for NeuroImaging in Psychiatry (ISNP), held on September 29-October 3, 2004 in Irvine, CA, TMIA’s founder, Turan M. Itil, M. D., presented a lecture describing the role of quantitative EEG (qEEG) and data bases in the early diagnosis of Alzheimer’s Disease (AD). Dr. Itil stated, “Since, according to published reports, anti- AD drugs are more effective in the early stages than later, it is important to diagnose AD as early as possible. We demonstrated in a very large project that qEEG can assist medical experts as an objective, additional procedure to make an early diagnosis of AD.” Dr. Itil furthermore suggested that a technique he and his colleagues developed, known as quantitative pharmaco-EEG (QPEEG), might aid in the process of selecting the “right” central nervous system (CNS) medication and dose for each individual patient. Dr. Itil’s team has been using QPEEG to measure the efficacy and determine useful dose-ranges of CNS-effective drugs for over 30 years. During that time, his team used QPEEG to assist most of the world’s leading pharmaceutical companies at one time or another in many of their CNS drug development programs.
Mr. Carlos Cardillo, TMIA’s VP, added, “Our goal and motto is to fight what could -- if not addressed soon -- become an AD epidemic in the coming years, through early AD diagnosis and, hopefully, delay or even prevention of the onset of its symptoms. And we believe that this might be accomplished by the use of qEEG in our Alzheimer’s Centers.”
TMI Alzheimer’s Centers, Inc. is a publicly-traded Delaware corporation formed to offer State-of-the-Science medical diagnostic and treatment
options to actual and potential sufferers of Alzheimer’s Disease (AD) & other memory disturbances in 2002 by concerned physicians and business people.
With 1 mobile and 4 stationary diagnostic and treatment facilities currently serving the NY/NJ/CT Metropolitan area, the company has provided AD screening
services to hundreds of patients.
NOTE: SOME INFORMATION CONTAINED HEREIN MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS,
UNCERTAINTIES AND OTHER FACTORS OVER WHICH THE COMPANY HAS LITTLE OR NO
CONTROL. SUCH FACTORS INCLUDE GENERAL ECONOMIC AND BUSINESS CONDITIONS AND
COMMERCIAL ACCEPTANCE OF THE COMPANY’S PRODUCTS AND SERVICES. in collaboration with: NEW YORK INSTITUTE FOR MEDICAL RESEARCH, INC. & MANHATTAN-WESTCHESTER MEDICAL SERVICES, PC.
TMI Alzheimer’s Centers, Inc.
CONTACT: Turan M. Itil, M. D., Chairman and CEO of TMI Alzheimer’sCenters, Inc., +1-212-696-1827
